Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

McGill University

$159,950.00

Validation of the CUX1 Expression Signature as an RT-PCR-Based Prognostic Tool

EF 2010-11

Résumé
Breast cancer remains a challenge to treat, in part, due to the heterogeneity of the disease. Some breast cancers respond to specific treatments, others do not, while approximately 50% of breast cancers may not require any treatment except surgical removal of the tumor. Correct decision-making in each case is crucial since all treatments are associated with short and long-term negative effects. The problem is that current methods of diagnostic fail to correctly identify patients who can be spared from unnecessary treatment and those who must be treated with aggressive therapies. We have discovered a test that can accurately predict which patients are at risk and which patients are not. We propose to modify our test to make it easy to use in clinical laboratories and then to carry a study to demonstrate its superiority over currently available assays on the marker.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
213059
Name
Nepveu Alain
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Proof of Principle
Projecttitle
Validation of the CUX1 Expression Signature as an RT-PCR-Based Prognostic Tool
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$159,950
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Bioinformatics; Breast Cancer; Expression Profiling; Rt-Qpcr
Abstract
Breast cancer remains a challenge to treat, in part, due to the heterogeneity of the disease. Some breast cancers respond to specific treatments, others do not, while approximately 50% of breast cancers may not require any treatment except surgical removal of the tumor. Correct decision-making in each case is crucial since all treatments are associated with short and long-term negative effects. The problem is that current methods of diagnostic fail to correctly identify patients who can be spared from unnecessary treatment and those who must be treated with aggressive therapies. We have discovered a test that can accurately predict which patients are at risk and which patients are not. We propose to modify our test to make it easy to use in clinical laboratories and then to carry a study to demonstrate its superiority over currently available assays on the marker.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nepveu, Alain
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $159,950~ $0~